FrancophonIA/ELRC3.0 huggingface dataset:
English: Impaired healing***.
Estonian: Endokriinsüstee mi häired hüpotüreoos**, TSH tõus‡**
English: Optimal medical management (i.e. treatment or therapy) for nausea, vomiting, and diarrhoea should be initiated prior to any lenvatinib therapy interruption or dose reduction; however, gastrointestinal toxicity should be actively treated in order to reduce the risk of development of renal impairment or renal failure (see section 4.4 Renal failure and impairment).
Estonian: Toksilisust seedetraktile tuleb aga aktiivselt ravida, et vähendada neerukahjustuse või -puudulikkuse riski (vt lõik 4.4 „Neerupuudulikkus ja neerukahjustus“).
English: There are limited data on patients with hepatic impairment in RCC.
Estonian: Andmed neerurakk-kartsinoomiga ja maksakahjustusega patsientide kohta on piiratud.
English: Renal failure j, †, ‡ Renal impairment‡ Blood creatinine increased Blood urea increased
Estonian: Vaskulaarsed häired verejooksd, †,‡, hüpertensioone,‡, hüpotensioon aneurüsmid ja arteridissektsiooni d
English: Cardiac dysfunction (see section 4.4)
Estonian: Südamehäired (vt lõik 4.4)
English: The following terms have been combined: a: Thrombocytopenia includes thrombocytopenia and decreased platelet count.
Estonian: Trombotsütopeenia hõlmab trombotsütopeeniat ja trombotsüütide arvu vähenemist.
English: Chemotherapeutic agents
Estonian: Keemiaravi ravimid
English: Cardiac dysfunction
Estonian: Südamehäire
English: Palmar-plantar erythrodysaesthesia syndrome Palmar erythema Rash Alopecia
Estonian: I LISA RAVIMI OMADUSTE KOKKUVÕTE
English: • have a history of abnormal passageways (known as a fistula) between different organs in the body or from an organ to the skin
Estonian: • kui teil on esinenud organismis elunditevahelisi või naha ja elundi vahelisi ebanormaalseid ühenduskanaleid (mida nimetatakse fistliteks).
English: A yellowish-red body and yellowish-red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 4 mg” on the body.
Estonian: Kollakaspunase keha ja kollakaspunase kaanega, ligikaudu 14,3 mm pikkune, kaanel musta värvi märgistus „Є” ja kehal „LENV 4 mg”.
English: • The recommended daily dose of Kisplyx is 18 mg once a day (one 10 mg capsule and two 4 mg capsules) in combination with one 5 mg tablet of everolimus once a day.
Estonian: • Kisplyx'i soovitatav ööpäevane annus on 18 mg üks kord ööpäevas (üks 10 mg kapsel ja kaks
English: Pancreatitis
Estonian: Rahvus
English: Vomiting Nausea Oral inflammationg Oral painh
Estonian: Vere ja lümfisüsteemi häired trombotsütopeeniaa lümfopeeniaa põrna infarkt
English: The most frequently observed adverse drug reactions at these doses were hypertension, nausea, diarrhea, fatigue, stomatitis, proteinuria, headache, and aggravation of PPE.
Estonian: Kliinilistes uuringutes esines ravimi manustamisel ka juhuslikke vigu ühekordsetes annustes 40 kuni 48 mg. Nende annuste puhul kõige sagedamini esinenud kõrvaltoimed olid hüpertensioon, iiveldus, kõhulahtisus, väsimus, suupõletik, proteinuuria, peavalu ja palmoplantaarse erütrodüsesteesia sündroomi süvenemine.
English: Partial responses
Estonian: Osalisi ravivastuseid
English: What Kisplyx is
Estonian: Mis ravim on Kisplyx
English: • loss of appetite or weight loss
Estonian: • isutus või kehakaalu langus
English: Non-GI fistula
Estonian: Seedetraktiväline fistul
English: Any grade
Estonian: Aeg-ajalt
English: With regard to safety, the Agency noted an acceptable safety profile.
Estonian: Ohutuse kohta märkis amet, et ohutusprofiil on vastuvõetav.
English: Praluent received a marketing authorisation valid throughout the EU on 23 September 2015.
Estonian: Praluent on saanud müügiloa, mis kehtib kogu ELis, 23. septembril 2015.
English: If the desired response is not achieved after 4 to 8 weeks of treatment, the doctor can increase or decrease the dose.
Estonian: Kui soovitud ravivastust ei saavutata 4-8-nädalase ravi järel, võib arst annust suurendada või vähendada.
English: Further information on Praluent can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Praluent.
Estonian: Lisateave Praluenti kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Praluent.
English: What measures are being taken to ensure the safe and effective use of Praluent?
Estonian: Mis meetmed võetakse, et tagada ravimi Praluent ohutu ja efektiivne kasutamine?
English: Praluent (alirocumab)
Estonian: Praluent (alirokumaab)
English: What is Praluent and what is it used for?
Estonian: Mis on Praluent ja milleks seda kasutatakse?
English: The European Medicines Agency decided that Praluent's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Praluenti kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: The usual starting dose is 75 mg every two weeks, but patients requiring bigger reductions of blood fat levels may start with 150 mg every two weeks or 300 mg every 4 weeks.
Estonian: Tavaline algannus on 75 mg iga 2 nädala järel, kuid patsientidel, kelle vere rasvasisaldust on vaja rohkem vähendada, võib kasutada algannust 150 mg iga 2 nädala järel või 300 mg iga 4 nädala järel.
English: Other information about Praluent
Estonian: Muu teave Praluenti kohta
English: As for all medicines, data on the use of Praluent are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Praluenti kasutamise kohta pidevat järelevalvet.
English: Patients or their carers can inject the medicine once they have been trained by a healthcare professional.
Estonian: Patsiendid või nende hooldajad tohivad ravimit iseseisvalt süstida pärast seda, kui nad on saanud tervishoiutöötajalt asjakohase väljaõppe.
English: Why is Praluent authorised in the EU?
Estonian: Miks Praluent ELis heaks kiideti?
English: Praluent can also be used without a statin in patients who cannot take statins.
Estonian: Praluenti tohib kasutada ka ilma statiinita, kui patsient ei saa statiine võtta.
English: What are the risks associated with Praluent?
Estonian: Mis riskid Praluentiga kaasnevad?
English: Side effects reported with Praluent are carefully evaluated and any necessary action taken to protect patients.
Estonian: Praluenti kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: For more information about using Praluent, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Praluenti kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Praluent have been included in the summary of product characteristics and the package leaflet.
Estonian: Praluenti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Some patients are required to be on a low fat diet.
Estonian: Osa patsiente peab järgima väherasvast dieeti.
English: Praluent is available as a solution for injection in a pre-filled syringe or pre-filled pen (75 and 150 mg).
Estonian: Seda turustatakse süstelahusena eeltäidetud süstaldes või eeltäidetud pensüstaldes (75 ja 150 mg).
English: In patients with atherosclerotic heart disease, Praluent reduced the number of cardiovascular events, in particular heart attacks and strokes.
Estonian: Aterosklerootilise südamehaigusega patsientidel vähendas Praluent kardiovaskulaarsete sündmuste, eriti südameinfarkti- ja insuldijuhtude arvu.
English: Before starting treatment with Praluent, other causes of excess cholesterol and abnormal fat levels in the blood should be excluded.
Estonian: Enne Praluentiga toimuva ravi alustamist peavad liigse kolesterooli ja vere ebanormaalse rasvasisalduse muud põhjused olema välistatud.
English: Praluent has been studied in 10 main studies involving over 5,000 adult patients with hypercholesterolaemia (including patients with heterozygous familial disease) and mixed dyslipidaemia.
Estonian: Praluenti uuriti 10 põhiuuringus, milles osales üle 5000 täiskasvanud patsiendi, kellel oli hüperkolesteroleemia (sh heterosügootse päriliku haigusega patsiendid) ja segatüüpi düslipideemia.
English: How is Praluent used?
Estonian: Kuidas Praluenti kasutatakse?
English: Atherosclerotic heart disease
Estonian: Aterosklerootiline südamehaigus
English: The active substance in Praluent, alirocumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a specific enzyme called PCSK9.
Estonian: Praluenti toimeaine alirokumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära ensüümi PCSK9 ja seondub sellega.
English: By attaching and blocking PCSK9, Praluent prevents the receptors from being broken down inside cells and therefore increases the number of these receptors on the cell surface, where they can attach to LDL-cholesterol and remove it from the bloodstream.
Estonian: Ensüümiga PCSK9 seondudes ja seda blokeerides takistab Praluent nende retseptorite lõhustumist rakkudes ning suurendab seega nende arvu raku pinnal, kus need seonduvad LDL-kolesterooliga ja eemaldavad selle vereringest.
English: Some studies compared Praluent with placebo (a dummy treatment) and others to another medicine for hypercholesterolaemia (ezetimibe).
Estonian: Mõnes uuringus võrreldi Praluenti platseeboga (näiv ravim), teistes muu hüperkolesteroleemiaravimiga (esetimiib).
English: Therefore, Praluent has been approved for use in patients who do not adequately respond to the maximum tolerated dose of statins or who cannot be given statins.
Estonian: Seetõttu on Praluenti kasutamine heaks kiidetud patsientidel, kellel ei teki statiinide maksimaalse talutava annusega piisavat ravivastust või kellele statiinid on vastunäidustatud.
English: The Agency noted that across all studies in patients with primary hypercholesterolaemia and mixed dyslipidaemia, including patients on maximum recommended doses of statins or those intolerant to them, treatment with Praluent led to a significant reduction in LDLcholesterol levels, which is a known risk factor for cardiovascular (affecting the heart and blood vessels) disease.
Estonian: Amet märkis, et kõigis uuringutes vähendas Praluent esmase hüperkolesteroleemia ja segatüüpi düslipideemiaga patsientidel, sh statiine soovitatavas maksimumannuses saavatel või neid mittetaluvatel patsientidel oluliselt LDL-kolesterooli sisaldust, mis on kardiovaskulaarse haiguse (südame- ja veresoonkonnahaiguse) teadaolev riskitegur.
English: This helps to reduce the amount of LDL-cholesterol in the blood.
Estonian: See aitab vähendada vere LDL-kolesterooli sisaldust.
English: This enzyme attaches to cholesterol receptors on the surface of liver cells and causes these receptors to be absorbed and broken down inside the cells.
Estonian: See ensüüm seondub maksarakkude pinnal olevate kolesterooliretseptoritega, mistõttu need retseptorid imenduvad ja lõhustuvad rakkudes.
English: It is also used to reduce the risk of heart problems and strokes in patients who have atherosclerotic cardiovascular disease (heart problems such as heart attack, stroke or other problems of the circulatory system caused by fatty deposits build up in the walls of the arteries).
Estonian: Ravimit kasutatakse ka südameprobleemide ja insuldi tekkeriski vähendamiseks patsientidel, kellel on aterosklerootiline kardiovaskulaarhaigus (nt südameinfarkt, insult või muud vereringesüsteemi probleemid, mis on tingitud rasva ladestumisest arteriseintes).
English: When given on top of standard treatment or on its own, Praluent produced a 24 to 36% greater reduction in blood levels of LDL-cholesterol than ezetimibe.
Estonian: Kui Praluenti kasutati lisaks standardravile või ainuravimina, vähendas see LDL-kolesterooli sisaldust veres 24-36% rohkem kui esetimiib.
English: These receptors control blood levels of cholesterol, especially LDLcholesterol, by removing it from the bloodstream.
Estonian: Need retseptorid reguleerivad kolesterooli, eelkõige LDL-kolesterooli sisaldust veres, eemaldades selle vereringest.
English: Praluent is a medicine for lowering levels of fat in the blood.
Estonian: Praluent on ravim, mida kasutatakse vere rasvasisalduse vähendamiseks.
English: The most common side effects with Praluent (which may affect up to1 in 10 people) are injection site reactions such as pain and redness, problems affecting the nose and throat such as colds, and itching.
Estonian: Praluenti kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on süstekoha reaktsioonid, nt valu ja punetus, nina- ja kurguprobleemid, nt külmetushaigused, ja sügelus.
English: Some studies looked at Praluent taken on its own, while others studied Praluent in combination with other fat-lowering medicines, including patients on the maximum recommended doses of statins.
Estonian: Mõnes uuringus vaadeldi Praluenti kasutamist ainuravimina ja teistes Praluenti kombinatsiooni muude rasvasisaldust vähendavate ravimitega, sh patsientidel, kes said statiine soovitatavas maksimumannuses.
English: Alirocumab also helps to reduce other fatty substances from blood in patients with mixed dyslipidaemia.
Estonian: Alirokumaab aitab vähendada ka muude rasvainete sisaldust segatüüpi düslipideemiaga patsientide veres.
English: These studies showed that when Praluent was given on top of a statin it led to a substantial reduction in blood levels of LDL-cholesterol (between 39 and 62% more than placebo) after 6 months of treatment.
Estonian: Uuringud tõendasid, et Praluenti kasutamisel lisaks statiinile vähenes 6-kuuse ravi järel LDL-kolesterooli sisaldus veres oluliselt (39-62% rohkem kui platseeboga).
English: It is used to reduce fat levels in adults with primary hypercholesterolaemia (high levels of blood cholesterol without an identifiable cause, often resulting from the person's genetic makeup) and mixed dyslipidaemia (abnormal levels of different fats in the blood, including cholesterol).
Estonian: Sellega vähendatakse vere rasvasisaldust täiskasvanutel, kellel on esmane hüperkolesteroleemia (vere tuvastatava põhjuseta suur kolesteroolisisaldus, millel on sageli geneetiline põhjus) ja segatüüpi düslipideemia (rasvade, sh kolesterooli ebanormaalne sisaldus veres).
English: In a study involving over 18,000 patients who had established heart disease, less than 10% of patients given Praluent had a cardiovascular event (meaning death, heart attack, stroke, chest pain due to problems with the blood flow to the heart leading to hospitalisation) during the study compared with over 11% of patients given placebo.
Estonian: Uuringus, milles osales 18 000 diagnoositud südamehaigusega patsienti, oli Praluenti kasutanute seas patsiente, kellel tekkis uuringu ajal kardiovaskulaarne sündmus (st hospitaliseerimist põhjustanud vereringehäiretest tingitud surm, südameinfarkt, insult, rindkerevalu), alla 10% ja platseebot (näiv ravim) saanud patsientide seas üle 11%.
English: The most common side effects leading to treatment discontinuation were local injection site reactions.
Estonian: Paiksed süstekoha reaktsioonid olid kõige sagedamad kõrvalnähud, mille tõttu ravi katkestati.
English: Praluent is used in combination with a statin or a statin and other fat-lowering medicines.
Estonian: Praluenti kasutatakse koos statiiniga või koos statiini ja muude vere rasvasisaldust vähendavate ravimitega.
English: The dose of Praluent is adjusted based on the levels of fats in blood and response to the medicine.
Estonian: Praluenti annust kohandatakse vere rasvasisalduse ja ravivastuse põhjal.
English: An overview of Praluent and why it is authorised in the EU
Estonian: Ülevaade ravimist Praluent ja ELis müügiloa väljastamise põhjendus
English: How does Praluent work?
Estonian: Kuidas Praluent toimib?
English: The injection is given under the skin of the abdomen, thigh or upper arm.
Estonian: Subkutaanne süst tehakse kõhu-, reie- või õlavarrepiirkonda.
English: It contains the active substance alirocumab.
Estonian: Ravim sisaldab toimeainena alirokumaabi.
English: What benefits of Praluent have been shown in studies?
Estonian: Milles seisneb uuringute põhjal ravimi Praluent kasulikkus?
English: The medicine can only be obtained with a prescription.
Estonian: Praluent on retseptiravim.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rapiscan on 6 September 2010.
Estonian: Euroopa Komisjon andis Rapiscani müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 6. septembril 2010.
English: A risk management plan has been developed to ensure that Rapiscan is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Rapiscani võimalikult ohutu kasutamine.
English: The ‘agreement rates' between the first and second scans were similar regardless of which of the two medicines were used for the second scan.
Estonian: Esimese ja teise uuringu kokkulangevus oli sarnane olenemata sellest, kumba kahest ravimist kasutati enne teist uuringut.
English: What measures are being taken to ensure the safe and effective use of Rapiscan?
Estonian: Mis meetmed võetakse, et tagada Rapiscani ohutu ja efektiivne kasutamine?
English: Rapiscan should only be used once within any 24-hour period.
Estonian: Rapiscani tohib kasutada 24 tunni jooksul ainult ühe korra.
English: The full EPAR for Rapiscan can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Rapiscani kohta on ameti veebilehel: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: The CHMP decided that Rapiscan's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Rapiscani kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Other information about Rapiscan:
Estonian: Muu teave Rapiscani kohta:
English: This is a summary of the European public assessment report (EPAR) for Rapiscan.
Estonian: See on ravimi Rapiscan Euroopa avaliku hindamisaruande kokkuvõte.
English: Patients must not take any medicines or products that contain methylxanthines (such as caffeine or theophylline) for at least 12 hours before receiving Rapiscan.
Estonian: Patsiendid ei tohi võtta ravimeid ega tooteid, mis sisaldavad metüülksantiine (nt kofeiini või teofülliini), vähemalt 12 tundi enne Rapiscani manustamist.
English: Because Rapiscan causes a rapid increase in heart rate and a fall in blood pressure, patients should remain sitting or lying down and be monitored frequently until the effects of the medicine have worn off.
Estonian: Et Rapiscan kiirendab kiiresti pulssi ja vähendab vererõhku, peavad patsiendid jääma istuma või lamama ning neid tuleb ravimi mõju ajal jälgida sageli.
English: Rapiscan must only be used in a hospital that has equipment for resuscitation and monitoring the patient.
Estonian: Rapiscani tohib kasutada ainult haiglas, kus on olemas elustusvahendid ja patsiendi jälgimise seadmed.
English: Rapiscan is for diagnostic use only.
Estonian: Rapiscan on ette nähtud kasutamiseks üksnes diagnostikas.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rapiscan.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: It is used in adult patients (aged 18 years or over) who are unable to exercise enough for a stress test.
Estonian: Seda kasutatakse täiskasvanud (vähemalt 18-aastastel) patsientidel, kes ei talu südame koormusuuringu jaoks vajalikku kehalist koormust.
English: The patient then undergoes the procedures for radionuclide myocardial perfusion imaging, starting with an injection of a radioactive substance 10 to 20 seconds after the sodium chloride injection.
Estonian: Seejärel alustakse patsiendil müokardi perfusiooni stsintigraafiat, mille jaoks süstitakse 10-20 sekundit pärast naatriumkloriidi süstet radioaktiivset ainet.
English: For more information about treatment with Rapiscan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Rapiscaniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Rapiscan regadenoson
Estonian: Rapiscan regadenosoon
English: The most common side effects with Rapiscan (seen in more than 1 patient in 10) are headache, dizziness, ST segment changes (an abnormal reading on the electrocardiogram or ECG), flushing (reddening of the skin), dyspnoea (difficulty breathing), gastrointestinal (stomach and gut) discomfort and chest pain.
Estonian: Rapiscani kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on peavalu, peapööritus, südame elektrokardiogrammi (EKG) ST-segmendi muutused, õhetus (nahapunetus), düspnoe (õhupuudustunne), ebamugavustunne maos ja sooles ning valu rinnus.
English: Rapiscan must not be used in patients with slow heart rate unless they have a pacemaker, unstable angina (a type of chest pain that changes in severity) that has not been controlled with treatment, severe hypotension (low blood pressure) or decompensated heart failure (when the heart does not work as well as it should).
Estonian: Rapiscani ei tohi kasutada patsiendid, kellel on südamerütmuriga (südamestimulaatoriga) korrigeerimata aeglane pulss, raviga reguleerimata ebastabiilne rinnaangiin (muutliku tugevusega valud rinnus), raske hüpotensioon (madal vererõhk) või dekompenseeritud südamepuudulikkus.
English: The results of scans using Rapiscan and adenosine were comparable.
Estonian: Rapiscani ja adenosiiniga ettevalmistatud uuringute tulemused olid võrreldavad.
English: Why has Rapiscan been approved?
Estonian: Miks Rapiscan heaks kiideti?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rapiscan, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Rapiscani omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What is the risk associated with Rapiscan?
Estonian: Mis riskid Rapiscaniga kaasnevad?
English: Before this type of scan, the patient's heart is usually put under stress by exercise such as walking or running on a treadmill to help dilate (widen) the blood vessels in the heart and increase the blood flow to the heart muscle.
Estonian: Enne sellist uuringut koormatakse patsiendi südant kehalise koormusega, näiteks kõndimise või jooksmisega jooksulindil, millega laiendatakse südame veresooni ja parandatakse südamelihase verevarustust.
English: In two main studies, around 2,000 adult patients first had a myocardial perfusion imaging scan performed using adenosine (another medicine used as a stress agent) followed by a second scan with either adenosine or Rapiscan.
Estonian: Kahes põhiuuringus, milles osales ligikaudu 2000 täiskasvanud patsienti, manustati patsientidele enne müokardi perfusiooni stsintigraafiat adenosiini (samuti aine, mille mõju südamele sarnaneb kehalise koormuse mõjuga) ja enne teist uuringut kas adenosiini või Rapiscani.
English: It is given as a 10-second injection of 400 micrograms into a vein immediately followed by an injection of sodium chloride (salt) solution.
Estonian: Rapiscani manustatakse 10 sekundit kestva 400 µg süstena veeni ja vahetult selle järel süstitakse naatriumkloriidi lahust (soolalahust).
English: For the full list of all side effects reported with Rapiscan, see the package leaflet.
Estonian: Rapiscani kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The main measure of effectiveness was based on the similarity between the results of the scans with Rapiscan and adenosine.
Estonian: Efektiivsuse põhinäitaja rajanes Rapiscani ja adenosiiniga ettevalmistatud uuringute tulemuste sarnasusel.